col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer Science and Business Media LLC: npj Vaccines
  original article Date Title Authors   All Authors
1 [GO] 2022―Jan―21 Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, Heidi Contreras, Veronica Karpinski, Katelyn Faircloth, et al. (+15)
2 [GO] 2022―Jan―10 Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters Lisa H. Tostanoski, Abishek Chandrashekar, Shivani Patel, Jingyou Yu, Catherine Jacob-Dolan, Aiquan Chang, et al. (+29)
3 [GO] 2021―Dec―21 “World in motion” - emulsion adjuvants rising to meet the pandemic challenges Derek T. O’Hagan, Robbert van der Most, Rushit N. Lodaya, Margherita Coccia, Giuseppe Lofano
4 [GO] 2021―Dec―20 Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2 Ria Lassaunière, Charlotta Polacek, Gregers J. Gram, Anders Frische, Jeanette Linnea Tingstedt, Maren Krüger, et al. (+11)
5 [GO] 2021―Dec―16 Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza Sudha Chivukula, Timothy Plitnik, Timothy Tibbitts, Shrirang Karve, Anusha Dias, Donghui Zhang, et al. (+24)
6 [GO] 2021―Dec―13 SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses Joshua M. Carmen, Shikha Shrivastava, Zhongyan Lu, Alexander Anderson, Elaine B. Morrison, Rajeshwer S. Sankhala, et al. (+11)
7 [GO] 2021―Dec―03 MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge Clement A. Meseda, Charles B. Stauft, Prabhuanand Selvaraj, Christopher Z. Lien, Cyntia Pedro, Ivette A. Nuñez, et al. (+3)
8 [GO] 2021―Dec―03 A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern Mitch Brinkkemper, Philip J. M. Brouwer, Pauline Maisonnasse, Marloes Grobben, Tom G. Caniels, Meliawati Poniman, et al. (+11)
9 [GO] 2021―Nov―30 A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection Claudio Counoupas, Matt D. Johansen, Alberto O. Stella, Duc H. Nguyen, Angela L. Ferguson, Anupriya Aggarwal, et al. (+18)
10 [GO] 2021―Nov―29 Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies Chaojie Zhong, Hongjie Xia, Awadalkareem Adam, Binbin Wang, Renee L. Hajnik, Yuejin Liang, et al. (+10)
11 [GO] 2021―Nov―29 Immune response against SARS-CoV-2 variants: the role of neutralization assays Alicja Maria Chmielewska, Anna Czarnota, Krystyna Bieńkowska-Szewczyk, Katarzyna Grzyb
12 [GO] 2021―Nov―18 Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant Mayuresh M. Abhyankar, Barbara J. Mann, Jeffrey M. Sturek, Savannah Brovero, G. Brett Moreau, Anjali Sengar, et al. (+7)
13 [GO] 2021―Nov―04 Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination Rafael Assis, Aarti Jain, Rie Nakajima, Algis Jasinskas, Saahir Khan, Anton Palma, et al. (+22)
14 [GO] 2021―Oct―28 Scientific rationale for developing potent RBD-based vaccines targeting COVID-19 Harry Kleanthous, Judith Maxwell Silverman, Karen W. Makar, In-Kyu Yoon, Nicholas Jackson, David W. Vaughn
15 [GO] 2021―Oct―28 A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge Kathryn McGuckin Wuertz, Erica K. Barkei, Wei-Hung Chen, Elizabeth J. Martinez, Ines Lakhal-Naouar, Linda L. Jagodzinski, et al. (+50)
16 [GO] 2021―Oct―25 Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore Bei Wang, Yun Shan Goh, Tessa Prince, Eve Zi Xian Ngoh, Siti Nazihah Mohd Salleh, Pei Xiang Hor, et al. (+12)
17 [GO] 2021―Oct―20 An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats Martijn A. Langereis, Irina C. Albulescu, Judith Stammen-Vogelzangs, Morindy Lambregts, Ken Stachura, Suzan Miller, et al. (+13)
18 [GO] 2021―Oct―14 INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, Jared Tur, Charles Reed, Richa Kalia, et al. (+18)
19 [GO] 2021―Sep―30 The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America Pablo Argote, Elena Barham, Sarah Zukerman Daly, Julian E. Gerez, John Marshall, Oscar Pocasangre
20 [GO] 2021―Aug―24 Neutralization of MERS coronavirus through a scalable nanoparticle vaccine Mona O. Mohsen, Dominik Rothen, Ina Balke, Byron Martina, Vilija Zeltina, Varghese Inchakalody, et al. (+7)
21 [GO] 2021―Aug―16 Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action Franz X. Heinz, Karin Stiasny
22 [GO] 2021―Aug―12 National control laboratory independent lot testing of COVID-19 vaccines: the UK experience Nicola J. Rose, Paul Stickings, Silke Schepelmann, Marc J. A. Bailey, Chris Burns
23 [GO] 2021―Aug―11 Benefit of COVID-19 vaccination accounting for potential risk compensation John P. A. Ioannidis
24 [GO] 2021―Aug―05 Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic Samir Andrade Mendonça, Reka Lorincz, Paul Boucher, David T. Curiel
25 [GO] 2021―Jul―22 A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19 Delphine C. Malherbe, Drishya Kurup, Christoph Wirblich, Adam J. Ronk, Chad Mire, Natalia Kuzmina, et al. (+7)
26 [GO] 2021―Jun―17 A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells Simon G. P. Funnell, Babak Afrough, John James Baczenas, Neil Berry, Kevin R. Bewley, Rebecca Bradford, et al. (+11)
27 [GO] 2021―May―14 Public attitudes toward COVID-19 vaccination: The role of vaccine attributes, incentives, and misinformation Sarah Kreps, Nabarun Dasgupta, John S. Brownstein, Yulin Hswen, Douglas L. Kriner
28 [GO] 2021―May―13 Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation Lauren M. Meyers, Andres H. Gutiérrez, Christine M. Boyle, Frances Terry, Bethany G. McGonnigal, Andres Salazar, et al. (+4)
29 [GO] 2021―May―13 Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2 Ian McDonald, Sam M. Murray, Catherine J. Reynolds, Daniel M. Altmann, Rosemary J. Boyton
30 [GO] 2021―May―10 ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets Glenn A. Marsh, Alexander J. McAuley, Gough G. Au, Sarah Riddell, Daniel Layton, Nagendrakumar B. Singanallur, et al. (+38)
31 [GO] 2021―Apr―22 Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine Natalie Thiel, Casey Selwyn, Georgina Murphy, Shmona Simpson, Ajoy C. Chakrabarti
32 [GO] 2021―Apr―21 Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases Velayudhan Mohan Kumar, Seithikurippu R. Pandi-Perumal, Ilya Trakht, Sadras Panchatcharam Thyagarajan
33 [GO] 2021―Apr―19 Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models Kirill V. Kalnin, Timothy Plitnik, Michael Kishko, Jinrong Zhang, Donghui Zhang, Adrien Beauvais, et al. (+32)
34 [GO] 2021―Apr―16 mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents Susanne Rauch, Nicole Roth, Kim Schwendt, Mariola Fotin-Mleczek, Stefan O. Mueller, Benjamin Petsch
35 [GO] 2021―Apr―14 Access to and equitable distribution of COVID-19 vaccine in low-income countries Krishna Prasad Acharya, Tirth Raj Ghimire, Supram Hosuru Subramanya
36 [GO] 2021―Apr―13 Considerations for bioanalytical characterization and batch release of COVID-19 vaccines Gautam Sanyal, Anna Särnefält, Arun Kumar
37 [GO] 2021―Mar―30 Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters Qingmei Jia, Helle Bielefeldt-Ohmann, Rachel M. Maison, Saša Masleša-Galić, Sarah K. Cooper, Richard A. Bowen, Marcus A. Horwitz
38 [GO] 2021―Mar―25 The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization Jing Zou, Xuping Xie, Camila R. Fontes-Garfias, Kena A. Swanson, Isis Kanevsky, Kristin Tompkins, et al. (+4)
39 [GO] 2021―Mar―19 Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease Joan E. M. van der Lubbe, Sietske K. Rosendahl Huber, Aneesh Vijayan, Liesbeth Dekking, Ella van Huizen, Jessica Vreugdenhil, et al. (+21)
40 [GO] 2021―Mar―19 Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 Hansam Cho, Yuyeon Jang, Ki-Hoon Park, Hanul Choi, Aleksandra Nowakowska, Hee-Jung Lee, et al. (+6)
41 [GO] 2021―Feb―22 SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates Nikolaos C. Kyriakidis, Andrés López-Cortés, Eduardo Vásconez González, Alejandra Barreto Grimaldos, Esteban Ortiz Prado
42 [GO] 2021―Feb―11 Promoting versatile vaccine development for emerging pandemics Joshua T. Monrad, Jonas B. Sandbrink, Neil G. Cherian
43 [GO] 2021―Jan―25 Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters Rebecca L. Brocato, Steven A. Kwilas, Robert K. Kim, Xiankun Zeng, Lucia M. Principe, Jeffrey M. Smith, Jay W. Hooper
44 [GO] 2021―Jan―04 SARS-CoV-2 structural features may explain limited neutralizing-antibody responses Martin F. Bachmann, Mona O. Mohsen, Lisha Zha, Monique Vogel, Daniel E. Speiser
45 [GO] 2020―Nov―03 Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections Jay Epstein, W. Martin Smid, Silvano Wendel, Daniel Somuah, Thierry Burnouf
46 [GO] 2020―Oct―23 Navigating facilitated regulatory pathways during a disease X pandemic Shmona Simpson, Ajoy Chakrabarti, David Robinson, Keith Chirgwin, Murray Lumpkin
47 [GO] 2020―Oct―16 Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2 Drishya Kurup, Christoph Wirblich, Holly Ramage, Matthias J. Schnell
48 [GO] 2020―Oct―08 Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein Alexander J. McAuley, Michael J. Kuiper, Peter A. Durr, Matthew P. Bruce, Jennifer Barr, Shawn Todd, et al. (+14)
49 [GO] 2020―Sep―28 Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses Rinke Bos, Lucy Rutten, Joan E. M. van der Lubbe, Mark J. G. Bakkers, Gijs Hardenberg, Frank Wegmann, et al. (+18)
50 [GO] 2020―Sep―04 Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein René Wintjens, Amanda Makha Bifani, Pablo Bifani
51 [GO] 2020―Jul―27 Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 Simon P. Graham, Rebecca K. McLean, Alexandra J. Spencer, Sandra Belij-Rammerstorfer, Daniel Wright, Marta Ulaszewska, et al. (+36)
52 [GO] 2020―Jul―06 Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic Leonardo M. R. Ferreira, Mohammed A. Mostajo-Radji
53 [GO] 2020―Jun―15 Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens Jayanthi Wolf, Samantha Bruno, Michael Eichberg, Risat Jannat, Sharon Rudo, Susan VanRheenen, Beth-Ann Coller
54 [GO] 2020―May―28 Universal coronavirus vaccines: the time to start is now Luca T. Giurgea, Alison Han, Matthew J. Memoli
55 [GO] 2020―May―25 Certainty of success: three critical parameters in coronavirus vaccine development David C. Kaslow
56 [GO] 2020―Apr―30 COVID-19 vaccines: breaking record times to first-in-human trials Young Chan Kim, Barbara Dema, Arturo Reyes-Sandoval
57 [GO] 2020―Mar―06 The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines Weilong Shang, Yi Yang, Yifan Rao, Xiancai Rao
58 [GO] 2019―Dec―06 Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts Raffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, Mohammad A. Behzadi, Damien Friel, Arvind Rajabhathor, et al. (+11)


[de][en]

Last change 2022―Jan―20 20:43:25 UTC

© Daten-Quadrat 2022       Done in 0.011 sec